Cargando…

Anti-transcriptional intermediary factor-1γ antibody-positive dermatomyositis in a patient with triple-negative breast cancer treated with adjuvant capecitabine

Detalles Bibliográficos
Autores principales:	Kessler, Alaina J., Para, Andrew, Niedt, George W., Klein, Paula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176165/ https://www.ncbi.nlm.nih.gov/pubmed/37188285 http://dx.doi.org/10.1016/j.jdcr.2023.02.016

Ejemplares similares

Anti-transcription Intermediary Factor1γ-antibody-positive Dermatomyositis Complicated by Dysphagia
por: Kurushima, Shota, et al.
Publicado: (2017)

SCLC, Paraneoplastic Dermatomyositis, Positive Transcription Intermediary Factor 1-γ, and Point Mutation in the Transcription Intermediary Factor 1-γ Coding Gene: A Case Report
por: Arnon, Johnathan, et al.
Publicado: (2021)

Case Report: IgA Nephropathy in a Patient With Anti-Transcription Intermediary Factor-1γ Antibody-Positive Dermatomyositis
por: Zhang, Suo, et al.
Publicado: (2022)

Small cell lung cancer and interstitial pneumonia associated with anti‐transcriptional intermediary factor‐1γ‐positive dermatomyositis
por: Kato, Toshio, et al.
Publicado: (2019)

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer
por: Sato, Yuki, et al.
Publicado: (2022)

The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody–positive dermatomyositis
por: Oldroyd, Alexander, et al.
Publicado: (2019)

Autoantibodies to transcription intermediary factor (TIF)1β associated with dermatomyositis
por: Satoh, Minoru, et al.
Publicado: (2012)

Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1γ Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy
por: Aritomi, Takafumi, et al.
Publicado: (2018)

Efficacy of Sequential Capecitabine on Adjuvant Chemotherapy of Triple-Negative Breast Cancer
por: Xi, Xun, et al.
Publicado: (2022)

Anti-transcription intermediary factor 1 gamma (TIF1γ) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature
por: Ono, Ryohei, et al.
Publicado: (2021)

Comment on: The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody–positive dermatomyositis: Reply
por: Oldroyd, Alexander, et al.
Publicado: (2019)

Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti‐transcriptional intermediary factor 1‐γ antibody‐positive dermatomyositis: A case report
por: Kim, Yoonjoo, et al.
Publicado: (2022)

Lung adenocarcinoma and anti‐transcriptional intermediary factor 1‐gamma positive dermatomyositis complicated with spontaneous oesophageal rupture
por: Saraya, Takeshi, et al.
Publicado: (2019)

A case of capecitabine-induced dermatomyositis
por: Saraswat, Neerja, et al.
Publicado: (2018)

My-Lupus: A case of anti-transcriptional intermediary factor 1-gamma antibody-positive dermatomyositis overlapping with discoid lupus erythematosus in an adult patient
por: Toker, Michelle, et al.
Publicado: (2023)

A Case of Dermatomyositis Along with Esophageal Cancer and Screening of Serum Transcriptional Intermediary Factor 1 Gamma Antibodies in Various Cancer Patients
por: Sumazaki, Makoto, et al.
Publicado: (2020)

Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report
por: Kubeček, Ondřej, et al.
Publicado: (2016)

Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients
por: de Boo, Leonora W., et al.
Publicado: (2022)

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
por: Asleh, Karama, et al.
Publicado: (2023)

The Zebrafish moonshine Gene Encodes Transcriptional Intermediary Factor 1γ, an Essential Regulator of Hematopoiesis
por: Ransom, David G, et al.
Publicado: (2004)

Transcriptional Intermediary Factor 1γ binds to the Anaphase-Promoting Complex/Cyclosome and promotes mitosis
por: Sedgwick, Garry G., et al.
Publicado: (2012)

The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis
por: Huo, Xingfa, et al.
Publicado: (2021)

Hepatic stellate cell–specific knockout of transcriptional intermediary factor 1γ aggravates liver fibrosis
por: Lee, Eun Ju, et al.
Publicado: (2020)

Analysis of human total antibody repertoires in TIF1γ autoantibody positive dermatomyositis
por: Megremis, Spyridon, et al.
Publicado: (2021)

Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy
por: Harada, Yumi, et al.
Publicado: (2022)

Efficacy and Safety of Capecitabine for Triple-Negative Breast Cancer: A Meta-Analysis
por: Xun, Xueqiong, et al.
Publicado: (2022)

Capecitabine in adjuvant radiochemotherapy for gastric adenocarcinoma
por: Oblak, Irena, et al.
Publicado: (2014)

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
por: Lluch, Ana, et al.
Publicado: (2020)

Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study
por: Li, Yi-Hui, et al.
Publicado: (2018)

Triple-Negative Breast Cancer with Dermatomyositis: A Case Report and Literature Review
por: Chen, Xiao, et al.
Publicado: (2022)

Coexisting TIF1γ-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1γ Antibody-positive Dermatomyositis
por: Nakanishi, Yu, et al.
Publicado: (2020)

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
por: Li, Junjie, et al.
Publicado: (2020)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
por: Zhang, Zilin, et al.
Publicado: (2021)

Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: a meta-analysis
por: Bai, Jie, et al.
Publicado: (2023)

A unique case of dermatomyositis associated with anti-TIF1γ antibody and chondrosarcoma
por: Dziwis, Jennifer, et al.
Publicado: (2019)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
por: Shah, Ami N, et al.
Publicado: (2020)

Successful peficitinib addition on anti-MDA5 antibody-positive dermatomyositis refractory to triple therapy and glucocorticoid reduction
por: Oba, Yuki, et al.
Publicado: (2022)

Marked Improvement of Anti-TIF1-γ Antibody-Positive Dermatomyositis After Chemoradiotherapy to Relevant Nasopharyngeal Cancer
por: Tomita, Natsuo, et al.
Publicado: (2021)

The Intermediary Metabolism of Pyrene
por: Harper, K. H.
Publicado: (1958)

Intermediary metabolism of the lung.
por: Fisher, A B
Publicado: (1984)

Cannot write session to /tmp/vufind_sessions/sess_mk6hgcddlbrccimusvsi3130cf